Head to Head Survey: TScan Therapeutics (NASDAQ:TCRX) and MDxHealth (NASDAQ:MDXH)

MDxHealth (NASDAQ:MDXH – Get Free Report) and TScan Therapeutics (NASDAQ:TCRX – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and valuation.

Earnings and Valuation

This table compares MDxHealth and TScan Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
MDxHealth $114.01 million 0.05 -$33.52 million ($0.75) -0.14
TScan Therapeutics $5.19 million 1.91 -$129.77 million ($0.88) -0.17

MDxHealth has higher revenue and earnings than TScan Therapeutics. TScan Therapeutics is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

MDxHealth has a beta of 1.81, suggesting that its share price is 81% more volatile than the S&P 500. Comparatively, TScan Therapeutics has a beta of 1.21, suggesting that its share price is 21% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for MDxHealth and TScan Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MDxHealth 1 4 1 0 2.00
TScan Therapeutics 1 3 2 0 2.17

MDxHealth presently has a consensus price target of $1.33, suggesting a potential upside of 1,134.57%. TScan Therapeutics has a consensus price target of $2.67, suggesting a potential upside of 1,727.74%. Given TScan Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe TScan Therapeutics is more favorable than MDxHealth.

Profitability

This table compares MDxHealth and TScan Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
MDxHealth -40.84% N/A -27.78%
TScan Therapeutics -2,219.19% -140.75% -61.90%

Institutional & Insider Ownership

82.8% of TScan Therapeutics shares are owned by institutional investors. 1.7% of MDxHealth shares are owned by company insiders. Comparatively, 13.8% of TScan Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

MDxHealth beats TScan Therapeutics on 8 of the 14 factors compared between the two stocks.

About MDxHealth

(Get Free Report)

MDxHealth is a molecular diagnostics company focused on tests that support the detection and management of urologic cancers, particularly prostate cancer. Its services are intended to help clinicians assess cancer risk and make more informed decisions about biopsies and treatment. The company’s products include SelectMDx, a urine-based test that helps assess the risk of clinically significant prostate cancer, and ConfirmMDx, a tissue-based test that can help guide decisions after a negative prostate biopsy.

About TScan Therapeutics

(Get Free Report)

TScan Therapeutics is a clinical-stage biotechnology company developing engineered T cell receptor (TCR) T cell therapies for cancer. Its approach is designed to equip a patient’s T cells to recognize and attack cancer cells bearing specific targets. The company’s research and development programs include therapies for blood cancers and solid tumors. TScan uses its technology platform to identify cancer-associated targets and develop TCRs directed at them, with the goal of creating treatments for patients whose cancers express those targets.

Receive News & Ratings for MDxHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MDxHealth and related companies with MarketBeat.com's FREE daily email newsletter.